Source: Targeted Oncology, June 2025
Findings from the investigator-initiated, noncomparative randomized phase 2 NEO-MEL-T study (NCT04139902) indicate a significant benefit in major pathologic response (MPR) with the addition of a T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitor, cobolimab, to PD-1 monotherapy in high-risk resectable melanoma.1
The study, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting by Meghan Mooradian, MD, medical oncologist at Massachusetts General Hospital, highlights an effective strategy to address unmet needs in patients who may not achieve optimal response with current standard-of-care immunotherapy